{"id":"W3163043692","doi":"10.1016/j.jacc.2021.05.003","title":"Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Population Health Research Institute; McMaster University; Hamilton Health Sciences","funders":"Janssen Pharmaceuticals; Bayer Corporation; Bayer Canada; American Heart Association","keywords":"Medicine; Rivaroxaban; Clinical endpoint; Revascularization; Aspirin; Stroke (engine); Cardiology; Internal medicine; Population; Vascular disease; Myocardial infarction; Randomized controlled trial; Surgery; Anesthesia; Warfarin; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003982779,0.0001260905,0.0006047274,0.00007008117,0.00003542602,0.00000854434,0.0001458432,0.00003360991,0.00002823913],"category_scores_gemma":[0.00009486161,0.00006765942,0.0003898097,0.0003961496,0.0002465069,0.00007335099,0.00005305587,0.0002258836,6.940335e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000142019,"about_ca_system_score_gemma":0.00023067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003428009,"about_ca_topic_score_gemma":0.000002321302,"domain_scores_codex":[0.9981996,0.000611791,0.0004737423,0.0001485373,0.0004027251,0.0001635453],"domain_scores_gemma":[0.9989032,0.00003030315,0.0004461964,0.000347183,0.0002253136,0.00004786587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.559246,0.003777428,0.161797,0.0004001933,0.007830853,0.007214082,0.002564875,0.01299144,0.1463654,0.0002295748,0.08961535,0.007967749],"study_design_scores_gemma":[0.05212253,0.004527795,0.9121192,0.0002522864,0.0014621,0.006293575,0.003015984,0.00009544806,0.001132213,0.00009959219,0.01859214,0.0002871367],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927974,0.00009585554,0.0002750208,0.005453342,0.0005439909,0.000419809,0.00001307258,0.000003045385,0.0003984584],"genre_scores_gemma":[0.9978623,0.00003288246,0.0002894849,0.0005396737,0.001056406,0.00002303819,0.000004329443,0.00001224087,0.0001796094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7503222,"threshold_uncertainty_score":0.2759071,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006755752166840405,"score_gpt":0.2430622178150727,"score_spread":0.2363064656482323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}